Tofersen VALOR Trial

Tofersen VALOR Trial

Overview

The VALOR trial (NCT02623699) was a landmark Phase 3 clinical trial evaluating tofersen (trade name Qalsody), an antisense oligonucleotide (ASO) therapy targeting the SOD1 gene, in patients with amyotrophic lateral sclerosis associated with SOD1 mutations[@tofersen2023]. This trial represented a major milestone in precision medicine for ALS, as it was the first gene-targeted therapy to receive FDA approval for a specific genetic subtype of the disease. Tofersen works by reducing the production of the toxic SOD1 protein, addressing the underlying cause of disease in patients with SOD1 mutations rather than merely treating symptoms.

Trial Details

| Attribute | Value |
|-----------|-------|
| NCT Number | NCT02623699 |
| Phase | Phase 3 |
| Status | Completed (with open-label extension) |
| Sponsor | Biogen |
| Enrollment | 108 patients (SOD1 mutation carriers) |
| Duration | 24 weeks (blinded period), 52-week OLE |
| Randomization | 2:1 (tofersen:placebo) |
| Primary Endpoint | ALSFRS-R change at Week 28 |
| FDA Approval | April 2023 |

Mechanism of Action

Genetic Basis of SOD1-ALS

Tofersen VALOR Trial

Overview

The VALOR trial (NCT02623699) was a landmark Phase 3 clinical trial evaluating tofersen (trade name Qalsody), an antisense oligonucleotide (ASO) therapy targeting the SOD1 gene, in patients with amyotrophic lateral sclerosis associated with SOD1 mutations[@tofersen2023]. This trial represented a major milestone in precision medicine for ALS, as it was the first gene-targeted therapy to receive FDA approval for a specific genetic subtype of the disease. Tofersen works by reducing the production of the toxic SOD1 protein, addressing the underlying cause of disease in patients with SOD1 mutations rather than merely treating symptoms.

Trial Details

| Attribute | Value |
|-----------|-------|
| NCT Number | NCT02623699 |
| Phase | Phase 3 |
| Status | Completed (with open-label extension) |
| Sponsor | Biogen |
| Enrollment | 108 patients (SOD1 mutation carriers) |
| Duration | 24 weeks (blinded period), 52-week OLE |
| Randomization | 2:1 (tofersen:placebo) |
| Primary Endpoint | ALSFRS-R change at Week 28 |
| FDA Approval | April 2023 |

Mechanism of Action

Genetic Basis of SOD1-ALS

Mutations in the SOD1 (Superoxide Dismutase 1) gene account for approximately 2% of all ALS cases and around 20% of familial ALS cases. Over 190 pathogenic variants have been identified in SOD1, with some of the most common including A4V, G93A, H46R, G85R, and D90A. These mutations cause ALS through a toxic gain-of-function mechanism rather than loss of enzymatic activity — the mutant SOD1 protein adopts aberrant conformations that lead to:

Protein Aggregation: Mutant SOD1 forms intracellular inclusions that sequester essential cellular proteins and impair proteostasis. These aggregates are found in motor neurons of SOD1-ALS patients and model systems[@gutmanis2023].

Mitochondrial Dysfunction: SOD1 aggregates localize to mitochondria, disrupting electron transport chain function and increasing reactive oxygen species (ROS) production. This contributes to energy failure in highly metabolic motor neurons.

Excitotoxicity: Mutant SOD1 alters glutamate transporter function, leading to increased extracellular glutamate and excitotoxic motor neuron injury.

Impaired Axonal Transport: SOD1 aggregates disrupt microtubule-based transport, impairing delivery of organelles and proteins to distal axonal regions.

Neuroinflammation: Mutant SOD1 activates microglia and astrocytes, creating a toxic inflammatory environment.

Antisense Oligonucleotide Strategy

Tofersen is a gapmer antisense oligonucleotide designed to hybridize with SOD1 mRNA and trigger RNase H1-mediated degradation[@benatar2018]:

Sequence Design: The ASO is complementary to a conserved region of SOD1 mRNA, targeting all known disease-causing variants.

RNase H1 Recruitment: Upon binding, the ASO-mRNA duplex recruits RNase H1, which cleaves the RNA strand, leading to rapid degradation.

Reduced Protein Translation: By degrading SOD1 mRNA, tofersen reduces translation of both mutant and wild-type SOD1 protein, lowering the overall burden of toxic SOD1.

Allele-Specificity: While tofersen reduces all SOD1, patients with SOD1-ALS have one mutant and one wild-type allele. Partial reduction of wild-type SOD1 is well-tolerated, as demonstrated by studies of SOD1 knockout mice which show minimal phenotype.

Delivery Method

Tofersen is administered via intrathecal (lumbar puncture) infusion, directly into the cerebrospinal fluid (CSF)[@petrov2017]. This route was chosen because:

• The blood-brain barrier limits systemically delivered ASOs from entering the CNS
• Intrathecal delivery achieves high concentrations in the spinal cord and brain
• The lumbar region allows direct access to CSF without crossing the blood-brain barrier
• Dosing is typically every 28 days (monthly)

Patient Population

Inclusion Criteria

SOD1 Mutation Spectrum

The trial enrolled patients with diverse SOD1 mutations:

| Mutation | Geographic Prevalence | Typical Phenotype |
|----------|----------------------|-------------------|
| A4V | North America (most common) | Rapid progression |
| G93A | Global | Moderate progression |
| H46R | Japan | Slow progression |
| G85R | Global | Variable progression |
| D90A | Scandinavia | Slow progression |

Trial Design

Phase 1/2 Study (Completed Previously)

Prior to VALOR, a Phase 1/2 study established safety and preliminary efficacy:

Dose Escalation: Multiple ascending dose cohorts Primary Outcomes: Safety, tolerability, CSF SOD1 reduction Key Finding: Dose-dependent reduction in CSF SOD1 protein (up to 36%)[@mill2022]

Phase 3 VALOR

Randomization: 2:1 randomization to tofersen or placebo

Blinded Period: 24 weeks of treatment

Primary Endpoint: Change in ALSFRS-R total score from baseline to Week 28

Secondary Endpoints:

• CSF SOD1 protein levels (pharmacodynamic marker)
• Neurofilament light chain (NfL) in CSF
• Slow vital capacity (SVC)
• Timed Up and Go (TUG)
• Overall survival

Results

Primary Endpoint

The VALOR trial did not meet its primary endpoint in the overall population at 28 weeks[@tofersen2023]:

• Placebo Group: Mean ALSFRS-R decline of 6.3 points
• Tofersen Group: Mean ALSFRS-R decline of 5.5 points
• Difference: 0.8 points (p=0.21, not statistically significant)

Biomarker Results (Key Findings)

The trial demonstrated robust pharmacodynamic activity:

CSF SOD1 Reduction:

• Tofersen Group: 36% mean reduction from baseline
• Placebo Group: No change
• Significance: Highly significant (p<0.001)

Neurofilament Light Chain (NfL)[@turner2021]:

• Tofersen Group: Slower rate of NfL increase over 28 weeks
• Placebo Group: Faster rate of NfL increase
• Interpretation: Reduced neuronal injury in tofersen-treated patients

Open-Label Extension Results

Analysis of patients who received tofersen in the open-label extension revealed important insights:

Clinical Benefit Emergence: Patients who switched from placebo to tofersen in the OLE showed:

• Continued functional decline at the rate seen during blinded period
• No clear additional benefit at 52 weeks

• Slowing of decline that became more apparent over time
• Suggestion of benefit in slower progressors (baseline ALSFRS-R ≥35)

Subgroup Analyses

Post-hoc analyses suggested benefit in specific subgroups:

Patients with faster progression (baseline characteristics):

• Trend toward greater benefit in patients with higher baseline disease progression rate

• Greater treatment effect observed
• This may reflect a window of opportunity where intervention before extensive motor neuron loss is more effective

Regulatory Approval

FDA Decision

In April 2023, the FDA granted accelerated approval of tofersen for SOD1-ALS under the Accelerated Approval pathway. This decision was notable because:

Limited Traditional Efficacy: The primary endpoint was not met, but biomarker data provided substantial evidence of effect.

Biomarker as Surrogate Endpoint: Reduction in CSF SOD1 was accepted as a reasonably likely surrogate endpoint for clinical benefit.

Unmet Need: SOD1-ALS is a uniformly fatal disease with no disease-modifying treatments.

Patient Community Input: Strong advocacy from the ALS patient community influenced the decision.

Post-Approval Requirements

The FDA required post-marketing studies to confirm clinical benefit:

VALOR-OLE: Continued follow-up of VALOR participants to assess long-term outcomes

NEED: A confirmatory trial in a broader SOD1-ALS population

Clinical Significance

Precision Medicine in ALS

Tofersen represents the first successful application of precision medicine in ALS:

Genotype-Specific Treatment: Therapy is tailored to patients with a specific genetic mutation

Mechanism-Targeting: Treatment addresses the underlying molecular cause rather than symptoms

Blueprint for Other Genetic Subtypes: The approach informs development of ASOs for other ALS genes:

• C9orf72 (most common genetic ALS)
• [FUS](/genes/fus)
• [TARDBP](/genes/tardbp)

Comparison with Other ALS Therapies

| Therapy | Target | Mechanism | Patient Population |
|---------|--------|-----------|-------------------|
| Riluzole | Glutamate | Anti-excitotoxic | All ALS |
| Edaravone | Oxidative stress | Antioxidant | Specific subgroup |
| AMX0035 | ER + Mitochondria | Dual neuroprotection | All ALS |
| Tofersen | SOD1 mRNA | Gene silencing | SOD1 mutation only |

Challenges and Lessons

The VALOR trial highlighted several important considerations:

Clinical vs. Biomarker Endpoints: Demonstrating clinical benefit in ALS trials remains challenging. Biomarker reduction may not immediately translate to functional preservation.

Disease Stage Matters: Treatment effect may be greater in earlier-stage patients, suggesting importance of early intervention.

Trial Design for Gene Therapies: Traditional ALS trial designs may need modification for gene-silencing approaches where benefit may emerge slowly.

Future Directions

Broader Application

Research is ongoing to apply the ASO approach to other genetic forms of ALS:

C9orf72-ASO: Multiple programs in development for the most common genetic cause of ALS/FTD

FUS-ASO: Early-stage programs targeting FUS mutations

TARDBP-ASO: Preclinical development for TDP-43 pathology

Biomarker Development

Advances in biomarker research will improve future trials:

NfL作为Biomarker: Neurofilament light chain is being validated as a prognostic and pharmacodynamic marker

Therapeutic Monitoring: CSF NfL may help identify patients most likely to respond

Combination Approaches

Future trials may explore:

• Tofersen + other neuroprotective agents
• Gene therapy + small molecule combinations
• Stem cell transplantation with gene silencing

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [SOD1 Gene](/genes/sod1)
• [Antisense Therapy](/mechanisms/antisense-therapy)
• [Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl)
• [Precision Medicine in Neurodegeneration](/mechanisms/precision-medicine-neurodegeneration)
• [Mitochondrial Dysfunction in ALS](/mechanisms/mitochondrial-dysfunction-als)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)

External Links

• [ClinicalTrials.gov - NCT02623699](https://clinicaltrials.gov/ct2/show/NCT02623699)
• [PubMed - Tofersen NEJM 2023](https://pubmed.ncbi.nlm.nih.gov/38007185/)
• [Biogen Qalsody Information](https://www.biogen.com/)

References